Sort
39,280 grants matching “leukemia”
New control of oncogene activation in T-cell leukemia
$504,152Chengyu Liang · Wistar Institute · R01 · FY2023 · CA
Mechanistic and translational studies of CBF leukemia
$504,072Paul Liu · National Human Genome Research Institute · ZIA · FY2024 · HG
Stage-specific roles for Zmiz1 in Notch-dependent steps of early T-cell development
$503,927Mark Y Chiang · University Of Michigan At Ann Arbor · R01 · FY2022 · AI
Exploring microRNA degradation in T-cell acute lymphoblastic leukemia
$503,845Mingyi Xie · University Of Florida · R01 · FY2025 · CA
Exploring microRNA degradation in T-cell acute lymphoblastic leukemia
$503,845Mingyi Xie · University Of Florida · R01 · FY2023 · CA
Regulation of the Fanconi Anemia Pathway by Ubiquitination
$503,785Alan David D'andrea · Dana-Farber Cancer Inst · R01 · FY2014 · DK
Th17 generation, action and therapeutic relevance in chronic lymphocytic leukemia
$503,583Nicholas Chiorazzi · Feinstein Institute For Medical Research · R01 · FY2022 · CA
Development of Novel PROTACs Targeting the ENL YEATS Domain for Treating MLL-rearranged Leukemias
$503,533Jian Jin · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · CA
Preclinical evaluation of small molecules with proven benefit in FA animal models
$503,528Markus Grompe · Oregon Health & Science University · P01 · FY2019 · HL
Retrovirus Biology
$503,513Alan Rein · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Transporters and hematopoietic toxicity
$503,435John D Schuetz · St. Jude Children'S Research Hospital · R01 · FY2016 · CA
Preclinical evaluation of small molecules with proven benefit in FA animal models
$503,402Markus Grompe · Oregon Health & Science University · P01 · FY2020 · HL
Cancer and Leukemia Group B - The Ohio State University
$503,136Clara D Bloomfield · Ohio State University · U10 · FY2010 · CA
Development of Novel PROTACs Targeting the ENL YEATS Domain for Treating MLL-rearranged Leukemias
$503,120Jian Jin · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · CA
Modulation of Endoplasmic Reticulum Associated Degradation to Support Ex Vivo Expansion of Hematopoietic Stem Cells
$503,097Qing Li · University Of Michigan At Ann Arbor · R01 · FY2024 · HL
Modulation of Endoplasmic Reticulum Associated Degradation to Support Ex Vivo Expansion of Hematopoietic Stem Cells
$503,097Qing Li · University Of Michigan At Ann Arbor · R01 · FY2025 · HL
Center for Environment-Mediated Drug Resistance in Pediatric Cancer
$503,090Yves A Declerck · Children'S Hospital Of Los Angeles · U54 · FY2011 · CA
Quality of Life of African American Cancer Survivors
$503,073University Of Illinois At Chicago · R01 · FY2004 · CA
Implications of PARP1 in myelodysplastic syndromes and targeted therapy
$503,056Dang Hai Nguyen · University Of Minnesota · R01 · FY2024 · HL
Modified CMV-specific T cells to Target HIV
$502,933Stephen Edward Braun · Tulane University Of Louisiana · R33 · FY2017 · AI
Signal Transduction by Non-transmembrane PTPs
$502,926Benjamin G. Neel · Beth Israel Deaconess Medical Center · R37 · FY2007 · CA
TARGETING AML-STROMAL INTERACTIONS
$502,925John F Dipersio · Washington University · R01 · FY2012 · CA
Project 4: Secondary Cancers Among NF1 Cancer Survivors
$502,899Jean Nakamura · Indiana University Indianapolis · U54 · FY2017 · CA
Genetically Modified Gamma Delta T Cells to Target SIV Reservoirs
$502,807Namita Rout · Tulane University Of Louisiana · R33 · FY2021 · AI
LACE-Bio-II: Identification, validation and implementation of prognostic and/or p
$502,749Lesley Katie Seymour · Queen'S University At Kingston · R01 · FY2016 · CA